

# Prothromplex

Prothromplex is a drug used to **treat acute** severe **bleeding conditions** caused by **acquired coagulopathy**. These are mainly conditions during direct (e.g. NOAC) and indirect ( Warfarin ) anticoagulant therapy. It is a mixture of human coagulation factors II, VII, IX, X, and Protein C. It is produced in a package containing 600 IU in 20 ml. For an idea, it contains as much coagulation factors as 600 ml of frozen plasma.

## Indications

With regard to possible thrombogenic complications of drug use, the indication must be carefully considered. It is about:

- life-threatening bleeding conditions - given by the volume of blood loss or localization (hemorrhage into the CNS )
- conditions requiring urgent surgery - typically NPB, including damage control surgery

## Serious Side effects

Development of thromboembolic disease , disseminated intravascular coagulopathy allergic reaction, heart failure or myocardial infarction

## Dosage

Dosage recommendations are given in units of IU/kg of patient weight.

- in hypocoagulable states in patients on WarfarinTemplate:HVLP

Hodnota INR	Dávka léčiva
2,0-3,9	25 IU/kg
4,0-6,0	35 IU/kg
nad 6,0	50 IU/kg

- in hypocoagulable states in patients on NOAC therapy - recommended dose 30-50 IU/kg

 **NOACs cannot be guided by INR**

## Links

### Related articles

- anticoagulants

### Reference

1. *Summary of Product Characteristics, PROTHROMPLEX TOTAL NF: PROTHROMPLEX TOTAL NF* [online]. SÚKL, 2015 [cit. 2016-4-15]. Available from: <https://www.sukl.cz/modules/medication/detail.php?code=0075634>
2. ↑Jump up to:a b c FENGER-ERIKSEN, C. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications. *Acta Anaesthesiologica Scandinavica* [online]. 58 n. l., 2014 (6), 651-659 [cit. 2016-04-15]. DOI: 10.1111/aas.12319.
3. ↑Jump up to:a b c PEACOCK, W. Frank. Emergency Management of Bleeding Associated With Old and New Oral Anticoagulants. *Clinical Cardiology* [online]. 2012, 35 (12), 730-737 [cit. 2016-04-15]. DOI: 10.1002/clc.22037.
4. ↑Jump up to:a b *Life-threatening bleeding - recommended practice consensus opinion* [online]. Prague: Czech Hematology Society ČLS JEP [cit. 2016-4-15]. Available from: [http://www.hematology.cz/doporuceni/klinika-files/Doporuceni\\_CHS\\_CLS\\_JEP-Zivot\\_ohrozujici\\_krvaceni.pdf](http://www.hematology.cz/doporuceni/klinika-files/Doporuceni_CHS_CLS_JEP-Zivot_ohrozujici_krvaceni.pdf) .